IMD business school for management and leadership courses

Amgen’s enterprise-wide AI strategy positions the company at the forefront of biotechnology innovation, spanning drug discovery, development, manufacturing, and commercialization. CTO David Reese highlights AI as a transformative force, complemented by the 2024 appointment of Sean Bruich as Senior Vice President of AI and Data to lead cross-enterprise adoption. Amgen has further invested in global capabilities, launching a $200m Technology and Innovation Center in Hyderabad, India, to scale AI talent and applications. 

In R&D, Amgen employs generative biology models and Nvidia’s DGX SuperPOD™ “Freyja” at deCODE genetics to simulate millions of protein designs across more than 200 petabytes of genomic data, creating a human diversity atlas to advance precision medicine. Strategic collaborations with Nvidia and Deepcell expand applications in cell morphology and biomarker identification. On the operational side, Amgen integrates Microsoft 365 Copilot® for 20,000 employees to automate routine tasks, while its new Ohio biomanufacturing facility leverages AI for efficiency, sustainability, and quality. 

Amgen’s workforce strategy includes apprenticeship programs that upskill nontraditional talent, fostering inclusion and future-ready skills. Ethical deployment is governed by Amgen’s AI Vision, an AI Governance Council, and adherence to NIST’s Trustworthy AI framework, ensuring fairness, transparency, and security across its global operations.